In this video interview, Kimberly Tableman, founder & CEO, ESPERO, highlights how data standards are empowering the use of artificial intelligence.
In a recent video interview with Applied Clinical Trials, Kimberly Tableman, founder & CEO, ESPERO, discussed the challenges and trends in protocol development for clinical trials. She also highlighted technological advancements, such as data interoperability standards like ICH M11 and CDISC, and how they are expected to streamline protocol development and support generative AI in 2025.
ACT: What do you think should be top of mind for clinical operations executives going in 2025?
Tableman: I think there's a number of different things, but I think the data interoperability part that I just spoke of, and leveraging the standards, again, from the ICH M11 all the way through enabling that digital data flow, but what it really empowers again, is artificial intelligence. We are seeing the use of AI, and we talk a lot right now about artificial intelligence with a human in the loop, so I think for where we're at right now in pharma, I think that clinical operations executives need to be looking at it, but I think also realizing that we're not yet at the advent where artificial intelligence is taking away jobs and so on and so forth, you still need people that are looking at what the AI generates and saying, “Yeah, this works, or it doesn't work.” For us, for example, we use artificial intelligence to bring in a bolus of objectives, endpoints, inclusion/exclusion, criteria, that are options that you can put into the protocol, but a human being is still looking at that information and making a decision about, “Yeah, I want to leverage this objective or this endpoint, I want to put in this inclusion or exclusion into the study design overall.” I think getting comfortable with a trust but verify, taking some steps in that direction, to start getting more comfortable with artificial intelligence will be really helpful.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.